Deupirfenidone, a potential new treatment for idiopathic pulmonary fibrosis, is set to be tested in a phase 3 trial this year after a successful phase 2b trial and meeting with the FDA, according to a ...
A new risk stratification model for idiopathic pulmonary fibrosis could shift treatment from passive monitoring to active, goal-oriented care.
The FDA granted orphan drug designation to deupirfenidone, also known as LYT-100, for treating patients with idiopathic pulmonary fibrosis, according to a press release from PureTech Health.The ...
1d
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
Rein expects to enroll patients through mid-2027, with interim data anticipated in the second half of 2026.
Leerink Partners 2026 Global Healthcare Conference March 8 – 11, 2026, Miami, Florida Fireside Chat: March 11, 8:40 a.m. ET Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, ...
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group ...
Abbvie (ABBV) announced an update on their ongoing clinical study.
The FINANCIAL — Boehringer Ingelheim will present new data from its broad respiratory portfolio, which includes recently approved Spiolto Respimat (tiotropium ...
The study identified 32 differentially expressed proteins in IPF, highlighting cytokine dysregulation as a key molecular feature of the disease. Five hub proteins—FGF2, HGF, HBEGF, ERBB3, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results